Re
"It's most unlikely that one could approach a huge sales team mostly taking orders for established products and expect that they could drive a new technology disruptive product into a particular market."
Is this a view you have held since Celgene first signed the rofr?
The prevailing sentiment amongst the loyal followers has always been of Celgene, as a company, on the back foot in their negotiations with Mesoblast, and driven by the "opportunity cost" if they did not partner.
I sense this view is shifting; I am left wondering if, like Teva before them, Celgene will soon be considered a bunch of bone-headed number crunchers.
- Forums
- ASX - By Stock
- MSB
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-47
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B |
Open | High | Low | Value | Volume |
95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 72752 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 205100 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.005 |
5 | 57985 | 1.000 |
1 | 50000 | 0.995 |
2 | 20525 | 0.990 |
1 | 10000 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.035 | 190122 | 7 |
1.045 | 39714 | 5 |
1.050 | 21696 | 6 |
1.060 | 9750 | 2 |
1.065 | 5780 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online